

CURRICULUM VITAE

April 2016

CAPT Daniel S. Budnitz, MD, MPH

Director, CDC Medication Safety Program
Division of Healthcare Quality Promotion
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention (CDC)
1825 Century Center Boulevard, Mailstop D-26
Atlanta, GA 30345
Tel: 404-498-0634
Email: dbudnitz@cdc.gov

EDUCATION AND TRAINING

1998	MD	Emory University School of Medicine, Atlanta, GA
1997	MPH (Epidemiology)	Emory Rollins School of Public Health, Atlanta, GA
1993	BA (Government)	Harvard University, Cambridge, MA

POSTGRADUATE TRAINING

2001–2003	Epidemic Intelligence Service	CDC, Atlanta, GA
1999–2001	Internal Medicine Residency	Hospital of the University of Pennsylvania, Philadelphia, PA
1998–1999	Internal Medicine Internship	Hospital of the University of Pennsylvania, Philadelphia, PA

CERTIFICATION AND LICENSURE

2001–2021	Diplomat, American Board of Internal Medicine
2003–2018	DEA License
2001–2017	Medical License, Georgia
2001–2002	Medical License, Pennsylvania

FACULTY APPOINTMENTS

2007–2013	Clinical Assistant Professor, Department of Internal Medicine, Emory University School of Medicine
2002–2006	Clinical Assistant Professor, Department of Family and Preventive Medicine, Emory University School of Medicine

PUBLIC HEALTH SERVICE PROFESSIONAL EXPERIENCE

05/2005–present	Director, Medication Safety Program Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases, CDC Billet: O-6 (Chief Medical Officer, Applied Public Health)
07/2003–05/2005	Medical Officer II/III (Epidemiology) Division of Injury and Disability Outcomes and Programs National Center for Injury Prevention and Control, CDC Billet: O-3 (01CC201) / O-4 (01CC202)

06/2001–06/2003

Medical Officer II (Epidemiology)

Epidemiology Program Office, CDC

Assigned to: Division of Injury and Disability Outcomes and Programs

Billet: O-3, (01CC201)

LEADERSHIP OF COMMITTEES AND WORKING GROUPS

National Public-Private Partnerships

- **Founder**, *PROTECT* (Preventing Overdoses and Treatment Errors in Children Taskforce), 2008–present.

National Standards Setting Organizations

- **Co-Lead**, ASTM Task Group WK41534 New Practice for Evaluation of Non-Metered Flow Control Devices for Liquid Consumer Products, ASTM International Committee D10 on Packaging, 2012–present.
- **Co-Lead**, National Council of Prescription Drug Programs (NCPDP) Work Group 10 (Pharmacy Services) Task Group to draft recommendations for standardizing the dosing designation on prescription container labels of oral liquid medications, 2012-2014.

Inter-Agency Committees and Working Groups

- **Co-chair**, *CDC-FDA* Joint Workgroup on Pediatric Cough and Cold Product Safety, Chair of Scientific Subgroup, 2008–2010.
- **Co-chair**, *HHS* Workgroup on Anti-Influenza Medication Adverse Events Surveillance, 2004–2005.

COMMITTEE AND WORKING GROUP SERVICE

Inter-Departmental Advisory Boards and Working Groups

2012–present	Steering Committee, Federal Interagency Working Group on Adverse Drug Event Prevention, <i>DHHS</i>
2008–present	Permanent Member, Drug Safety Oversight Board, Center for Drug Evaluation and Research, <i>FDA</i>
2015–2019	Permanent Member, Endocrinology and Metabolic Drugs Advisory Committee (EMDAC)
2013–2015	Temporary Member, Endocrinology and Metabolic Drugs Advisory Committee (EMDAC), <i>FDA</i>
2011, 2014	Temporary Member, Psychopharmacologic Drugs Advisory Committee (PDAC), <i>FDA</i>
2009–2010	Veterans Health Administration (VHA) Geriatrics and Extended Care Pharmacy Management Workgroup, <i>Department of Veterans Affairs</i>
2008–2010	Leadership Coordinating Council of the Patient Safety & Clinical Pharmacy Services Collaborative, <i>HRSA</i>
2008	Part 15 Public Hearing on Over the Counter Cough and Cold Medications for Pediatric Use, <i>FDA</i>
2008	Public Workshop Panel. Maximizing the Public Health Benefit of Adverse Event Collection Throughout the Product Life Cycle, <i>FDA</i>
2007–2008	Federal Advisory Panel of the Sentinel Network to Promote Medical Product Safety, <i>FDA</i>
2006	Adverse Drug Event Reporting and Notification Working Group, <i>American Health Informatics Community (AHIC)</i>
2003	Medication Terminology Workgroup. <i>Consolidated Health Informatics (CHI)</i> Initiative

Inter-Agency Advisory Boards and Working Groups

2015	Key Informant for Evidence-based Practice Center Report “Patient Safety Practices in Ambulatory Settings, <i>AHRQ</i>
2015	Technical Expert Panel for the Value of Poison Centers for Medicare Beneficiaries, <i>HRSA</i>

2008–2010 Technical Expert Panel for the Patient Safety & Clinical Pharmacy Services Collaborative, *HRSA*
 2006–2008 Federal Agency Work Group for Medicare Patient Safety Monitoring System, *CMS*
 2006–2008 Technical Expert Panel for Medicare Patient Safety Monitoring System, *CMS*
 2005 Technical Expert Panel for Medicare Part D Medication Measures, *CMS*
 2004–2005 Expert Panel on Co-Occurring Disorders and Emerging Issues in Opioid Treatment, *SAMHSA*

Non-Governmental National Expert Panels and Advisory Boards

2015-present Scientific Advisory Committee for Project ACHIEVE (Achieving Patient-Centered Care and Optimized Health In Care Transitions by Evaluating the Value of Evidence), *PCORI*
 2013 Expert Panel to Evaluate the Use of Health IT to Reduce Adverse Events, funded by *Office of the National Coordinator for Health Information Technology (ONC)*
 2007–2010 Advisory Board for Project BOOST (Better Outcomes for Older Adults through Safe Transitions) *Society of Hospital Medicine (SHM)*
 2008–2009 Geriatric Care Transitions Technical Expert Panel, *National Committee for Quality Assurance (NCQA)*
 2007 Patient Safety Stakeholder Forum, *United States Pharmacopeia*
 2004–2008 Expert Advisory Panel for Warfarin Education Campaign, *SOS Rx*
 2003–2004 Patient Safety Special Interest Group. *Health Level Seven (HL7)*

Agency-wide Committees and Working Groups

2007–2009 Patient Safety Workgroup, Healthy Healthcare Settings Goal Team, *CDC*
 2004–2005 Expert Advisory Panel for a Controlled Health Thesaurus, National Center for Injury Prevention and Control, *CDC*
 2003 Committee to Revise CDC–FDA Inter-Agency Memoranda of Understanding, *CDC*
 2001–2004 Healthcare Safety Working Group, *CDC*

PUBLIC HEALTH SERVICE DEPLOYMENTS

New York, NY Volunteered for the first HHS response team deployed for the terrorist attack on the World Trade Center. Arrived in New York City within hours of the collapse of the Towers on 9/11. Led the rapid assessment of injuries with New York City Department of Health as an epidemiologist, clinical consultant, and database developer (11 days, 2001)

Chapel Hill, NC Co-led investigation of unintentional poisoning deaths and served as clinical expert (4 days, 2002)

Raleigh, NC Assisted North Carolina state health department conduct rapid injury surveillance for hurricane Isabel response as expert consultant in rapid injury assessment and database developer (5 days, 2003).

Atlanta, GA Epidemiologist and medical consultant for CDC Emergency Operations SARS State Support Team (12 days, 2003)

Tallahassee, FL Assisted the Florida state health department as injury epidemiologist and subject matter expert for hurricane Frances response (2 days, 2004)

Atlanta, GA Subject matter expert in medication safety for HHS Medkit Project (15 days, 2005)

Baltimore, MD Led Rapid Ebola Response (REP) Teams to ensure healthcare worker safety as Washington, DC area hospitals and health departments prepared to treat Ebola Virus Disease patients (8 days, 2014)

PUBLIC HEALTH SERVICE AWARDS (in order of precedence)

2009	Meritorious Service Medal
2005	Commendation Medal
2007	Achievement Medal
2003	Citation
2002	Outstanding Unit Citation (awarded again 2005, 2006, 2010, 2010)
2005	Unit Commendation (awarded again 2007, 2014)
2002	Crisis Response Service Award
2007	Field Medical Readiness Badge
2006	Regular Corps Ribbon
2003	Commissioned Corps Training Ribbon

NON-PHS INDIVIDUAL HONORS & AWARDS (selected)

2014	<i>Save the Children</i> REAL Award Honoree in Public Health Officer Category
2013	<i>Institute for Safe Medication Practices (ISMP)</i> Cheers Award for PROTECT Initiative for successful implementing innovative, proactive medication error reduction strategies
2004	Secretary's Award for Distinguished Service for contribution to SARS response, DHHS
2004	Honor Award for contributions to SARS response, CDC
1997	<i>Alpha Omega Alpha (AOA)</i> Honor Society, Emory University School of Medicine
1995	Anne Elizabeth and Harper Gaston Service Scholarship, Emory University School of Medicine
1995	Ciba-Geigy Award for Outstanding Community Service, Emory University School of Medicine
1993-1998	Robert W. Woodruff Fellow in Medicine, Emory University School of Medicine

MENTORSHIP

- Epidemic Intelligence Service (EIS), Primary Supervisor, CDC
(b) (6)
- Epidemic Intelligence Service (EIS), Secondary Supervisor, CDC
(b) (6)
- Masters Field Thesis Advisor, Rollins School of Public Health of Emory University
(b) (6)
- Pharmacy Residency Research Mentor, Atlanta VA Medical Center
(b) (6)

NON-PHS WORK EXPERIENCE

2007–2014	Clinical Assistant Professor, Internal Medicine Emory University School of Medicine Atlanta Veterans Administration (VA) Medical Center, Atlanta, GA <ul style="list-style-type: none">- Practices general internal medicine at the Atlanta VA Medical Center (2007-2011)- Lectures medical students, medical residents, and public health students
-----------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- 2002–2006 **Clinical Assistant Professor, Family and Preventive Medicine**
Emory University School of Medicine
Grady Hospital System, Atlanta, GA
- Primary care to patients at DeKalb-Grady Neighborhood Health Center
- 2000–2001 **Urgent Care Physician**
Student Health Services
University of Pennsylvania, Philadelphia, PA
- Urgent care to college and graduate students
- 1997 **Health Services Research Consultant**
Prudential Center for Healthcare Research
Atlanta, GA
- Identified time elapsed since training as the key physician characteristic associated with prescribing evidence-based cardiac therapies

PEER-REVIEWED RESEARCH PUBLICATIONS

32. Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, Mozersky RP, **Budnitz DS**. Emergency Department Visits for Adverse Events related to Dietary Supplements. *N Engl J Med* 2015;373:1531-40.
31. Lovegrove MC, Weidle NJ, **Budnitz DS**. Trends in Emergency Department Visits for Unsupervised Pediatric Medication Exposures, 2004-2013. *Pediatrics* 2015;136:e821-9.
30. Lovegrove MC, Mathew J, Hampp C, Governale L, Wysowski DK, **Budnitz DS**. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. *Pediatrics* 2014;134:e1009-16.
29. Hampton LM, Daubresse M, Chang HY, Alexander GC, **Budnitz DS**. Adult emergency department visits for psychiatric drug adverse events. *JAMA Psychiatry* 2014;71:1006-14.
28. Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, **Budnitz DS**. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. *JAMA Intern Med* 2014; 174:678-86.
27. **Budnitz DS**, Lovegrove MC, Rose KO. Adherence to label and device recommendations for over-the-counter pediatric liquid medications. *Pediatrics* 2014;133:e283-e290.
26. See I, Shehab N, Kegler SR, Laskar R, MD, **Budnitz DS**. Emergency department visits and hospitalizations for digoxin toxicity—United States, 2005–2010. *Circ Heart Fail* 2014;7:28-34.
25. Hampton LM, Nguyen BD, Edwards JR, **Budnitz DS**. Cough and cold medication adverse events after market withdrawal and labeling revision. *Pediatrics* 2013;132:1047-54.
24. Jones SC, **Budnitz DS**, Sorbello A, Mehta H. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions. *Pharmacoepidemiol Drug Saf* 2013;22:1099-1106.
23. Lovegrove, MC, Hon S, Geller RJ, Rose KO, Hampton LM, Bradley J, BS, BA, **Budnitz DS**. Efficacy of flow restrictors in limiting access of liquid medicines by young children *J Pediatr* 2013;163:1134-1139.e1.
22. **Budnitz DS**, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events among older Americans. *N Engl J Med* 2011;365:2002-2012.

21. **Budnitz DS**, Lovegrove MC, Crosby AE. Emergency department visits for overdoses of acetaminophen-containing products. *Am J Prev Med* 2011;40:585-92.
20. Manthripragada AD, Zhou EH, **Budnitz DS**, Lovegrove MC, Willy ME. Characterization of Acetaminophen Overdose-Related Emergency Department Visits and Hospitalizations in the United States. *Pharmacoepidemiol Drug Saf* 2011;20:819-26.
19. Lovegrove MC, Shehab N, Hales CM, Poneleit K, Crane E, **Budnitz DS**. Emergency department visits for antiviral adverse events during 2009 pandemic influenza A (H1N1). *Public Health Rep* 2011;126:312-7.
18. Shehab N, Schaefer MK, Kegler SR, **Budnitz DS**. Adverse events from cough and cold medications after a market withdrawal of infant products. *Pediatrics* 2010;126:1100-7.
17. Shehab N, Sperling LS, Kegler SR, **Budnitz DS**. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. *Arch Intern Med* 2010;170:1926-33.
16. Classen DC, Jaser L, **Budnitz DS**. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. *Jt Comm J Qual Patient Saf* 2010;36:12-21.
15. Blossom D, Noble-Wang J, Su J, Pur S, Chemaly R, Shams A, Jensen B, Pascoe N, Gullion J, Casey E, Hayden M, Arduino M, **Budnitz DS**, Raad I, Trenholme G, Srinivasan A. Multistate outbreak of *Serratia marcescens* bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes. *Arch Intern Med* 2009;169:1705-11.
14. Schillie SF, Shehab N, Thomas KE, **Budnitz DS**. Medication overdoses leading to emergency department visits among children. *Am J Prev Med* 2009;37:181-7.
13. Willy M, Kelly JP, Nourjah P, Kaufman DW, **Budnitz DS**, Staffa J. Emergency department visits attributed to selected analgesics, United States, 2004-2005. *Pharmacoepidemiol Drug Saf* 2009;18:188-195.
12. Shehab N, Patel PR, Srinivasan A, **Budnitz DS**. Emergency department visits for antibiotic-associated adverse events. *Clin Infect Dis* 2008;47:735-43. Epub Early Release 2008 Aug 11.
11. Schaefer MK, Shehab N, Cohen AL, **Budnitz DS**. Adverse events from cough and cold medications in children. *Pediatrics* 2008;121:783-787. Epub Early Release 2008 Jan 28.
10. Cohen AL, **Budnitz DS**, Weidenbach KN, Jernigan DB, Schroeder TJ, Shehab N, Pollock DA. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. *J Pediatr* 2008;152: 416-421.
9. **Budnitz DS**, Shehab N, Kegler SR, Richards CL. Emergency department visits for adverse drug events in older adults: the contribution of potentially inappropriate medication use. *Ann Intern Med* 2007;147:755-765.
8. Jung MA, **Budnitz DS**, Mendelsohn AB, Weidenbach KN, Nelson TD, Pollock DA. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (NEISS-CADES). *Medical Care* 2007;45 (suppl 2):S96-S102.
7. **Budnitz DS**, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Anest JL. National surveillance of emergency department visits for outpatient adverse drug events. *JAMA* 2006;296:1858-66.

6. Paulozzi LJ, **Budnitz DS**, Xi Y. Increasing deaths from opioid analgesics in the United States. *Pharmacoepidemiol Drug Saf* 2006;15:618-27.
5. Conn J, Annest JL, Ryann G, **Budnitz DS**. Nonwork-related finger amputations in the United States, 2001-2002. *Ann Emerg Med* 2005;45:630-5.
4. **Budnitz DS**, Pollock D, Mendelsohn AB, Weidenbach KA, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. *Ann Emerg Med* 2005;45:197-206.
3. Fehrenbach SN, **Budnitz DS**, Gazmararian JA, Krumholtz HM. Physician characteristics and the initiation of beta-blocker therapy after acute myocardial infarction in a managed care population. *Am J Manag Care* 2001;7:717-23.
2. Tulchinsky TH, Handsher R, Melnick JL, Abu Shabaan D, Neumann M, Abed Y, **Budnitz D**. Immune status to various strains of wild poliovirus among children in Gaza immunized with live attenuated oral vaccine alone compared with a combination of live and inactivated vaccines. *J of Vir Dis* 1994;1:5–13.
1. Hartzell HC and **Budnitz D**. Differences in effects of forskolin and an analog on calcium currents in cardiac myocytes suggest intra- and extracellular sites of action. *Mol Pharmacol* 1992;41:880-8.

EDITORIALS & INVITED COMMENTARIES

5. **Budnitz DS**, Lovegrove MC. The last mile: taking the final steps in preventing pediatric pharmaceutical poisonings. *J Pediatr* 2012;160:190-2.
4. **Budnitz DS**, Salis S. Preventing medication overdoses in young children: an opportunity for harm elimination. *Pediatrics* 2011;127:e1597-9.
3. **Budnitz DS**. Agreement Between Drugs-to-Avoid Criteria and Expert Assessments of Problematic Prescribing—Invited Commentary. *Arch Intern Med* 2009;169:1332-34.
2. **Budnitz DS**. Inappropriate medication use in hospitalized older adults – is it time for interventions? *J Hosp Med* 2008;3:87-90.
1. **Budnitz DS**, Layde PM. Outpatient drug safety: new steps in an old direction. *Pharmacoepidemiol Drug Saf* 2007;16:160-5.

RESEARCH BRIEFS, MMWRs & LETTERS TO EDITOR

14. Hampton LM, Daubresse M, Chang HY, Alexander GC, **Budnitz DS**. Emergency Department Visits by Children and Adolescents for Antipsychotic Adverse Events. *JAMA Psychiatry*. 2015;72:292-4.
13. Lovegrove M, Hampton LM, **Budnitz DS**, Geller AI. Emergency department visits and hospitalizations for buprenorphine ingestion by children – United States, 2010-2011. *MMWR* 2013; 62:56. (Reprinted in *JAMA* 2013;309:1667-8.)
12. **Budnitz DS**, Lovegrove ML, Shehab N. Reply – Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med* 2012;366:859-60.
11. Shehab N, **Budnitz DS**. Time to Change the Paradigm: From “potentially inappropriate” to real patient harms. *Ann Intern Med* 2011;171:473-4.

10. Patel PR, Kallen AJ, **Budnitz DS**. Product-related adverse events in hemodialysis patients: improving recognition and response. *Am J Kidney Dis* 2010;55:972-3.
9. **Budnitz DS**, Lewis LL, Shehab N, Brinkrant D. CDC and FDA response to risk of confusion in dosing Tamiflu Oral Suspension. *N Engl J Med* 2009;361:1913-4 ["Online First" release Sep 30, 2009].
8. **Budnitz DS**, Shehab N, Kegler SR, Richards CL. Is it safe to conclude that Beers criteria medications led to few adverse events? *Ann Intern Med* 2008;148:629.
7. Infant deaths associated with cough and cold medications – Two states, 2005. *MMWR* 2007; 56:1-4.
6. Cohen AL, Jhung MA, **Budnitz DS**. Stimulant medications and attention deficit-hyperactivity disorder. *N Engl J Med* 2006;354:2294-5.
5. Unintentional medication exposures among young children, United States, 2001-2003. *MMWR* 2006; 55:1-5. (Reprinted in *JAMA* 2006;295:882-4.)
4. Assessing the National Electronic Injury Surveillance System – Cooperative Adverse Drug Event Surveillance Project – Six Sites, United States, January 1–June 15, 2004. *MMWR* 2005;54:380-3.
3. Ballesteros MF, **Budnitz DS**, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in deaths due to methadone in North Carolina. *JAMA* 2003; 290:40.
2. Rapid assessment of injuries among survivors of the terrorist attack on the World Trade Center—New York City, September 11, 2001. *MMWR* 2002;51:1-5. (Reprinted in *JAMA* 2002;287:835-838.)
1. **Budnitz D** and Neuman WR. Underuse of beta-blockers following myocardial infarction. *JAMA* 2001;285:1013.

PEER-REVIEWED ABSTRACTS & PRESENTATIONS (Last 5 years)

31. Lovegrove MC, Sapiano MR, Paul IM, Yin HS, Wilkins TL, **Budnitz DS**. Primary Care Provider Perceptions and Practices Regarding Dosing Units for Oral Liquid Medications. *Pediatric Academic Societies' Annual Meeting*. Vancouver, Canada. April 30-May 3, 2016.
30. Wright D, **Budnitz D**, Ling S, Moody-Williams J, Moy E. National Action Plan for Adverse Drug Event Prevention. *Academy Health Annual Research Meeting*. Minneapolis, MN, June 16, 2015.
29. Geller AI, Shehab N, Lovegrove M, Hampton L, Weidenbach K, **Budnitz D**. Emergency department visits for insulin adverse events—United States, 2007-2009. *American Diabetes Association 73rd Scientific Sessions*, Chicago, IL. June 21-25, 2013.
28. Additional peer reviewed abstracts and presentations available by request.

INVITED ABSTRACTS & PRESENTATIONS (Last 5 years)

28. "Safety of dietary supplements." *16th Annual Oxford International Conference on the Science of Botanicals & 5th Interim American Society of Pharmacognosy Meeting*. Oxford, MS, April 11-14, 2016.
27. "Preventing Medication Exposures in Young Children". *American College of Medical Toxicology*

Annual Scientific Meeting. Clearwater Beach, FL, March 28, 2015.

26. "Update on the PROTECT Initiative." *Consumer Healthcare Products Association Regulatory, Scientific & Quality Conference.* Washington, DC, May 13, 2014.
25. "Milliliter as the standard measure for dosing liquid medications." *National Council of Prescription Drug Programs 2013 Fall Educational Summit.* Portland, OR, November 5, 2013.
24. "Epidemiology of Adverse Drug Events." *American College of Clinical Toxicology Pre-Meeting Symposium.* Atlanta, GA. September 27, 2013.
23. "Strategies for harm reduction: what might work?" *American Association for the Study of Liver Disease Clinical Research Single Topic Conference: Acetaminophen Poisoning.* Atlanta, GA. June 9-10, 2012.
22. Additional invited abstracts and presentations available by request.

PEER REVIEWER

New England Journal of Medicine, 2015-present
JAMA, 2007-present
Annals of Internal Medicine, 2007-present
Archives of Internal Medicine, 2006-present
Journal of General Internal Medicine, 2007-present
Journal of Hospital Medicine, 2007-present
Pharmacoepidemiology and Drug Safety, 2007-present
Clinical Infectious Diseases, 2007-present
The Journal on Information Technology in Healthcare, 2006-present
Journal of Women's Health, 2008-present
Drugs & Aging, 2009-present
American Journal of Managed Care, 2009-present
American Journal of Emergency Medicine, 2010-present
Injury Prevention, 2010-present
Canadian Medical Association Journal, 2011-present
BMC Health Services Research, 2012-present
Critical Care Nurse, 2012-present
The Journal of Pediatrics, 2013-present
Applied Clinical Informatics, 2013-present
Mayo Clinic Proceedings, 2013-present
Drugs – Real World Outcomes, 2014-present
The Joint Commission Journal on Quality and Patient Safety, 2014-present
AIMS Public Health, 2015-present